Sivik Global Healthcare LLC Invests $1.26 Million in argenex SE $ARGX

Sivik Global Healthcare LLC purchased a new position in shares of argenex SE (NASDAQ:ARGX) in the 4th quarter, Holdings Channel.com reports. The firm purchased 1,500 shares of the company’s stock, valued at approximately $1,261,000.

Several other large investors have also modified their holdings of the stock. Greenleaf Trust raised its stake in shares of argenex by 2.8% during the fourth quarter. Greenleaf Trust now owns 619 shares of the company’s stock worth $521,000 after purchasing an additional 17 shares during the last quarter. Aaron Wealth Advisors LLC raised its stake in shares of argenex by 37.3% during the fourth quarter. Aaron Wealth Advisors LLC now owns 673 shares of the company’s stock worth $566,000 after purchasing an additional 183 shares during the last quarter. Portside Wealth Group LLC raised its stake in shares of argenex by 8.6% during the fourth quarter. Portside Wealth Group LLC now owns 633 shares of the company’s stock worth $532,000 after purchasing an additional 50 shares during the last quarter. Sound Income Strategies LLC purchased a new stake in shares of argenex during the fourth quarter worth approximately $28,000. Finally, Signaturefd LLC raised its stake in shares of argenex by 5.9% during the fourth quarter. Signaturefd LLC now owns 1,853 shares of the company’s stock worth $1,558,000 after purchasing an additional 104 shares during the last quarter. Hedge funds and other institutional investors own 60.32% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have issued reports on ARGX. Deutsche Bank Aktiengesellschaft upgraded argenex from a “hold” rating to a “buy” rating in a research report on Tuesday, March 10th. Guggenheim dropped their target price on argenex from $1,160.00 to $1,120.00 and set a “buy” rating on the stock in a research report on Friday, February 27th. Zacks Research upgraded argenex from a “strong sell” rating to a “hold” rating in a research report on Friday, February 20th. Weiss Ratings reiterated a “hold (c)” rating on shares of argenex in a research report on Wednesday, January 21st. Finally, Stifel Nicolaus boosted their target price on argenex from $1,028.00 to $1,248.00 and gave the stock a “buy” rating in a research report on Thursday, December 11th. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $1,016.22.

argenex Trading Up 2.3%

ARGX stock opened at $765.43 on Wednesday. The company has a market cap of $47.37 billion, a P/E ratio of 39.21, a P/E/G ratio of 1.23 and a beta of 0.46. argenex SE has a 52 week low of $510.05 and a 52 week high of $934.62. The company’s 50-day moving average price is $769.43 and its 200 day moving average price is $813.94.

argenex (NASDAQ:ARGX) last released its quarterly earnings data on Saturday, February 14th. The company reported $8.02 EPS for the quarter. argenex had a net margin of 30.42% and a return on equity of 38.51%. On average, equities research analysts expect that argenex SE will post 3.13 earnings per share for the current year.

argenex Profile

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.